3B Blackbio DX's Q4 FY 2025-26 Quarterly Results
- 30 May 2026
Result Summary
- 3B Blackbio DX Ltd reported a 18.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 66.1%.
- Its expenses for the quarter were up by 6.3% QoQ and 107.7% YoY.
- The net profit decreased 56.3% QoQ and increased 22.0% YoY.
- The earnings per share (EPS) of 3B Blackbio DX Ltd stood at 11.44 during Q4 FY 2025-26.
Financial Statments for Q4 FY 2025-26
Total Income | 45.58 | 55.93 | 27.44 | -18.5% | 66.1% |
Total Expenses | 30.93 | 29.10 | 14.89 | 6.3% | 107.7% |
Profit Before Tax | 14.65 | 26.84 | 12.54 | -45.4% | 16.8% |
Tax | 4.84 | 4.40 | 4.50 | 10.0% | 7.6% |
Profit After Tax | 9.81 | 22.44 | 8.04 | -56.3% | 22.0% |
Earnings Per Share | 11.44 | 26.19 | 9.38 | -56.3% | 22.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
3B Blackbio DX Ltd operates within the biotechnology sector, focusing primarily on the development and production of diagnostic solutions. The company is known for its contributions to the medical and healthcare industries, particularly in the field of molecular diagnostics. 3B Blackbio DX Ltd is involved in the manufacturing of diagnostic kits and reagents, which are crucial for various medical tests and research applications. As of now, there is no specific information about recent major developments within the company.
Revenue
In the fourth quarter of fiscal year 2026 (Q4FY26), 3B Blackbio DX Ltd reported a total income of ₹45.58 crores. This represents a decrease of 18.5% compared to the previous quarter (Q3FY26), where the total income stood at ₹55.93 crores. However, when looking at the year-over-year (YoY) performance, the total income increased by 66.1% from ₹27.44 crores in Q4FY25. This growth over the year signifies a substantial increase in revenue compared to the same quarter the previous year, despite the quarter-over-quarter decline.
Profitability
The company experienced a profit before tax (PBT) of ₹14.65 crores in Q4FY26, which marks a significant reduction of 45.4% compared to ₹26.84 crores in Q3FY26. On a year-over-year basis, the PBT increased by 16.8% from ₹12.54 crores in Q4FY25. The profit after tax (PAT) for Q4FY26 was ₹9.81 crores, down by 56.3% from ₹22.44 crores in Q3FY26, but up by 22.0% when compared to ₹8.04 crores in Q4FY25. This trend in profitability metrics indicates a decrease in quarterly profit but an overall improvement from the previous year.
Operating Metrics
The total expenses for 3B Blackbio DX Ltd in Q4FY26 were reported at ₹30.93 crores, showing a 6.3% increase from ₹29.10 crores in Q3FY26, and a significant rise of 107.7% from ₹14.89 crores in Q4FY25. The tax expense for the quarter was ₹4.84 crores, which increased by 10.0% from ₹4.40 crores in the previous quarter and by 7.6% from ₹4.50 crores the year before. Earnings per share (EPS) for Q4FY26 was ₹11.44, reflecting a 56.3% decrease from ₹26.19 in Q3FY26, yet a 22.0% increase from ₹9.38 in Q4FY25. These metrics provide insight into operational costs and shareholder returns during the quarter.
FAQs
3B Blackbio DX Ltd announced its Q4 FY 2025-26 results on 30 May, 2026.
3B Blackbio DX Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of 3B Blackbio DX Ltd Q4 FY 2025-26 results include:
- Revenue: ₹45.58 crore
- Net Profit: ₹9.81 crore
- EBITDA: ₹18.64 crore
- Year-over-Year Growth: 66.1%
- Quarter-over-Quarter Growth: -18.5%
3B Blackbio DX Ltd reported a net loss of ₹9.81 crore in Q4 FY 2025-26, reflecting a 22.0% year-over-year growth.
3B Blackbio DX Ltd posted a revenue of ₹45.58 crore in Q4 FY 2025-26.